Search Medical Condition
Please enter condition
Please choose location from dropdown

Sungnam, Korea, Republic of Clinical Trials

A listing of Sungnam, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (321) clinical trials

A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation ...

Phase

0.0 miles

Learn More »

KM-819 for Patients With Parkinson's Disease

This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) following the escalation of single and multiple doses of KM-819. The study will consist of 2 parts. In Part A, ...

Phase

0.0 miles

Learn More »

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for safety and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be determined. Sym015 will be given at different dose levels on an every second week (Q2W) dosing schedule. Each patient will be given one ...

Phase

0.0 miles

Learn More »

A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients

The purpose of this study is to evaluate efficacy and safety of Choline alfoscerate and Donepezil for cognitive improvements of patients with cerebrovascular injury in Alzheimer patients

Phase

0.0 miles

Learn More »

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

The study consists of 3 parts: dose escalation (Part 1), dose expansion (Part 2), and dose exploration (Part 3). Part 1 will evaluate dose escalation of durvalumab in combination with monalizumab in adult subjects with select advanced solid tumor malignancies. Part 2 will evaluate further the identified dose of durvalumab ...

Phase

0.0 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with NDD-CKD

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

Objectives: To explore the appropriate dose of a therapeutic hepatitis B vaccine through the evaluation of safety, tolerability, and efficacy Subjects: Chronic hepatitis B carrier with normal ALT range Study hypothesis: The immune tolerance break and strong immune responses in the chronic hepatitis B carrier could be achieved with therapeutic ...

Phase

0.0 miles

Learn More »

Safety Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

Phase

0.0 miles

Learn More »

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 ...

Phase

0.0 miles

Learn More »

Post-Marketing Surveillance Study of Fycompa Film-coated Tablets in Korean Patients

The objective of this post-marketing surveillance study is to observe the safety profile of Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) in a normal clinical practice setting.

Phase N/A

0.0 miles

Learn More »